Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Emeli Chatterjee
A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver
Keywords metabolic dysfunction-associated steatotic liver disease non-alcoholic fatty liver disease proteomics diabetes liver-on-a-chip Introduction Metabolic-associated steatotic liver disease (MASLD)—affecting over 30% of individuals worldwide1—has emerged as a predominant driver of end-stage liver disease and an important contributor to a range of other chronic, life-limiting illnesses (e.g., cancer,2 cardiovascular disease,3 and renal dysfunction).4 MASLD presents a histological spectrum...
A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver
R.S. is supported in part by grants from the National Institutes of Health (NIH) and the American Heart Association (AHA). R.S. has served for a consultant for Amgen and Cytokinetics. R.S. is a co-inventor on a patent for ex-RNAs signatures of cardiac remodeling (not relevant to the current work). A.S.P. is supported by the AHA Strategically Focused Research Network in Cardiometabolic Disease. R.S., J.B., A.S.P. have filed for a patent relevant to the findings in this manuscript.
Circulating extracellular vesicles in human cardiorenal syndrome promote renal injury in Kidney on Chip system
Clinical MedicineCardiologyNephrology Open Access | 10.1172/jci.insight.165172 JCI Insight. https://doi.org/10.1172/jci.insight.165172. Copyright © 2023, Chatterjee et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. View PDF Abstract Background: Cardiorenal syndrome (CRS)—renal injury during heart failure (HF)—is linked to higher morbidity.
Exomap1 mouse: a transgenic model for in vivo studies of exosome biology
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling
Cardiac hypertrophy and associated heart fibrosis remain a major cause of death worldwide. Phytochemicals have gained attention as alternative therapeutics for managing cardiovascular diseases. These include the extract from the plant Terminalia arjuna, which is a popular cardioprotectant and may prevent or slow progression of pathological hypertrophy to heart failure. Here, we investigated the mode of action of a principal bioactive T.
Arjunolic Acid, a Peroxisome Proliferator-Activated Receptor Alpha Agonist Regresses Cardiac Fibrosis by Inhibiting Non-canonical TGF-β Signaling.
Author contributions: SS1 conceived the idea of the project. TB1 designed and conducted most of the experiments, analyzed the results and wrote the paper with SS1. EC1 assisted in most experiments with animals. JS2 and BK2 did most of the bioinformatic and biophysical studies and analysed the data. AR3 conducted protein modeling and protein-protein docking and analysed the data with SS3. VT4 did extraction and purification of arjunolic acid used in the study.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Emeli
Contact Emeli, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack